John Butler, Akebia CEO
February 23, 2022 01:27 PM ESTUpdated February 25, 12:42 PM
Financing
Pharma

Ake­bia scrapes to­geth­er $85M war chest to com­mer­cial­ize va­da as PDU­FA date looms

John Carroll

Editor & Founder

With its PDU­FA date loom­ing at the end of March, Ake­bia has re­vised its com­mer­cial­iza­tion deal with Vi­for, in­ject­ing a quick $85 mil­lion in­to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times